Login to Your Account

CABS 2018

U.S./China cross-border deals off to good start, but will 2018 be 'Legend'ary?

By Jennifer Boggs
Managing Editor

Friday, January 12, 2018

SAN FRANCISCO – A shifting regulatory climate and an increasing push for innovation combined with a staggering amount of capital is expected to significantly increase the rate of cross-border dealmaking between China firms and U.S.-based and multinational companies, experts predicted during the Chinese American Biopharmaceutical Society meeting Wednesday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription